Perioperative bleeding can be a serious life-threatening complication in adult patients undergoing cardiac surgery, given the older age and additional comorbidities present in this patient population. The standard treatment options include transfusion of blood components and surgical re-exploration. We report the first case of an elderly female patient treated with local administration of recombinant factor VIIa (rFVIIa) for intractable hemorrhagic pericardial effusion, which developed following a transcutaneous aortic valve replacement (TAVR) procedure for severe aortic stenosis. No thromboembolic phenomena or adverse effects were observed. Local administration of rFVIIa is an efficacious treatment option for cardiac surgery patients as opposed to systemic administration of rFVIIa, use of massive blood products, or surgical re-exploration.
However, the risk of periprocedural bleeding for TAVR may be lower than surgical aortic valve replacement as indicated by the PARTNER 1 trial. 3 Management for bleeding in these patients would typically include the transfusion of blood components if an anatomical source of cardiac bleeding is suspected. In these situations, the patient may require extracorporeal circulatory support, such as cardiopulmonary bypass (CPB), to evaluate for an anatomical source of Abbreviations CPB, cardiopulmonary bypass; CHF, congestive heart failure; CT, computed tomography; TAVR, transcutaneous aortic valve replacement; rFVIIa, recombinant factor VIIa; PTT, partial thromboplastin time; SAVR, standard aortic valve replacement 1 The University of Texas Health Science Center at Houston, Department of Pathology and Laboratory Medicine 2 Gulf Coast Pathology Associates, 3 The University of Texas Health Science Center at Houston, Internal Medicine, 4 The University of Texas Health Science Center at Houston, Center for Advanced Heart Failure *To whom correspondence should be addressed. vanyajaitly@gmail.com bleeding with surgical correction if identified. Recombinant factor VIIa (rFVIIa) is a hemostatic agent approved to treat acute bleeding and prevent surgical bleeding in patients with hemophilia A and B with inhibitors as well as patients with congenital FVII deficiency. 4 It has also been described in the literature to treat acute bleeding in an off-label use via both systemic and local administration. 5 Herein we describe a case of intractable hemorrhagic pericardial effusion, which developed postoperatively in an elderly nonsurgical candidate patient following TAVR, where localized infusion of rFVIIa was used to treat acute bleeding.
Case Presentation
A 90-year-old female with past medical history significant for coronary artery disease, for which she was on low dose aspirin, and aortic aneurysm was admitted for elective TAVR for severe symptomatic aortic stenosis with New York Heart Association (NYHA) class III-IV congestive heart failure (CHF). Echocardiography showed mean , and a left ventricular ejection fraction of 45% to 50%. Aortic annulus was symmetrically calcified and bulky on computed tomography (CT) angiogram. CT scan showed presence of thoracic aortic aneurysm measuring 5.7 cm in diameter. Her Society of Thoracic Surgery (STS) predicted risk was 11.5%, making her high-risk for standard aortic valve replacement (SAVR) as compared to a low-risk STS score being <4 in candidates for SAVR. Therefore she was a candidate for TAVR.
The patient underwent TAVR with a 23 mm Edward Sapien 3 device using transfemoral approach. The patient developed asystole and complete heart block (CHB) during the procedure, and a temporary pacemaker was placed for this. Upon successful deployment, the valve access site was closed and closure confirmed with angiogram. Intraoperative echocardiography demonstrated development of pericardial effusion. The patient remained hemodynamically stable. A percutaneous pericardial drain was placed, which drained 400 mL of hemorrhagic fluid. Protamine was administered to reverse the effect of heparin, with a complete reversal based on activated clotting time (ACT) and partial thromboplastin time (PTT). The patient was transferred to cardiac care unit in stable condition, but she became progressively hypotensive and bradycardic. She was coagulopathic and thrombocytopenic, with laboratory results showing an international normalization ratio (INR) of 1.33, fibrinogen of 164 mg/dL, platelet count of 90k/mL, and PTT of 35.3, with an additional output of 600 mL blood in an hour from the pericardial drain. Her hematocrit dropped to 19% from a baseline of 34%. She received 5 units of red blood cells, 2 units of fresh frozen plasma, 20 units of cryoprecipitate, 1 apheresis platelet unit, along with Amicar, postoperatively. After administration of all blood components, coagulation parameters were immediately measured and found to be normalized, but the patient continued to bleed. Given the continued bleeding and the fact that the patient was not stable for surgical exploration, the treating physician discussed alternative medical options with the family, and an agreement was made to proceed with local infusion of rFVIIa as a last-resort measure on postoperative day 0.
Administration of rFVIIa was performed after reconstitution per manufacturer's instructions at the patient's bedside to a final concentration of 1 mg of rFVIIa in 1 mL of diluent. The reconstituted 1 mg (15 µg/kg) of rFVIIa was then administered via a 3-way stopcock with a luer-lock as a bolus injection followed by flushing of the line with 10 mL of sterile saline and locking the pericardial drainage line. Thirty minutes later, the pericardial drainage line was reopened, and output had dramatically reduced. Over the next hour the pericardial drain output was 0 mL, and the patient stabilized hemodynamically. It was noted after administration of rFVIIa that the pericardial drainage continued to downtrend daily and completely resolved by the third postoperative day. Pericardial drainage was 103 mL total for the first postoperative day (approximately 4.2 mL/hr), 30 mL total for the second postoperative day (approximately 1.25 mL/hr) and 0 mL for the third postoperative day. After the use of rFVIIa, the patient only required 1 additional blood product, which was a unit of apheresis platelets given for consumptive thrombocytopenia (140k/mL to 98k/mL), as well as thrombocytopathy secondary to aspirin effect on postoperative day 1. The unit of apheresis platelets was given more than 24 hours after the patient had sustained hemostasis and hemodynamic stability, her improvement coinciding with the timing of administration of rFVIIa. The patient did not suffer from any thromboembolic complications. The pericardial drain was removed on postoperative day 5 with postremoval echocardiogram showing no significant pericardial effusion.
She was discharged to a skilled nursing facility on postoperative day 18. Her hospital course was prolonged due to episodes of atrial fibrillation, controlled with medication, as well as failure to achieve clearance by physical therapy with recommendations for discharge to a skilled nursing facility. On a follow-up clinic visit 4 months later, the patient was found to be doing well with an unremarkable physical exam.
Discussion
Currently the Food and Drug Administration has approved rFVIIa for use in multiple scenarios, including bleeding in hemophilia A or B patients with inhibitors, prophylaxis of surgical bleeding in hemophilia A or B patients with inhibitors, patients with acquired hemophilia with inhibitors, congenital deficiency of factor VII, and Glanzmann thrombasthenia with platelet refractoriness. 4 In addition to these approved indications, rFVIIa has also been used for a diverse range of off-label uses, such as acute bleeding in trauma and cardiac surgery patients, as well as patients with intracranial hemorrhage. In these settings, rFVIIa has been reported to be administered systemically, with doses ranging from 50 to 200 µg/kg in trauma cases to 5 to 160 µg/kg in cases of intracranial hemorrhage. In cases of cardiac surgeries with intractable bleeding, rFVIIa in doses from 35 µg/kg to 90 µg/kg has been used successfully to control bleeding. [6] [7] [8] The administration of rFVIIa in these off-label indications has led to reduction of transfusion requirements and bleeding in a multitude of cases. [9] [10] [11] Administration of rFVIIa in these off-label settings remains controversial, as several reports have been made of thromboembolic complications, including thromboembolic stroke, myocardial infarction, pulmonary emboli, and deep venous thrombosis.
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This is particularly important in cardiac surgery patients, as bleeding after cardiac surgeries can be associated with multiple factors including but not limited to residual heparin effect, coagulopathy, thrombocytopathy, hyperfibrinolysis, and surgical sources of bleeding requiring extensive use of blood products, which has been linked to reduced long-term survival. 13, 14 On the contrary, there is a risk for thromboembolic complications after cardiac surgeries. 15, 16 Greater risk of developing adverse effects is associated with systemic use of rFVIIa as multiple and larger doses may be required to control bleeding. Gill et al reported that systemic rFVIIa use in patients with cardiac surgeries is associated with increase in number of critical events including stroke and death as compared to placebo. 17 In our case, the patient developed an acute hemorrhagic pericardial effusion following a TAVR procedure. Given that the patient continued to have a high pericardial drain output following correction of her coagulopathy, it was most likely a mechanical etiology resulting from myocardial injury. Due to her advanced age and hemodynamic instability, it was determined that she was not a candidate for surgical intervention, and conservative management was to continue with use of blood products and Amicar to see if the bleeding would resolve on its own. Despite these interventions she continued to have excess bleeding requiring red blood cell transfusion support, at which time the decision was made to use rFVIIa to see if it would resolve her clinical bleeding.
Because the patient, at the time of its use, was not demonstrating coagulopathy and clinically had bleeding limited to the pericardium, the decision was made to use rFVIIa locally instead of systemically. The use of rFVIIa locally had been shown to be safe and effective in controlling diffuse alveolar hemorrhage (DAH) when administered intrapulmonary. 18 In this case series, doses were 30, 50, or 60 µg/kg administered as a single dose or 2 doses over 2 days. Ultimately in our case, a single 1 mg (15 µg/kg) dose was administered locally, since the patient did not have systemic coagulopathy but localized hemorrhage. A lower dose was chosen because a study examining the use of rFVIIa in patients with left ventricular devices showed improved hemostatic parameters with a "low dose" (10-15 µg/kg) similar to a high-dose group (30-70 µg/kg) as well as a significantly reduced incidence of thrombotic complications in the lowdose group. 19 Using rFVIIa in this form, we were able to achieve hemostasis without any adverse thrombotic complications. As an additional benefit, using rFVIIa in this manner resulted in administration of fewer blood components, ultimately reducing the patient's risk of transfusion-related adverse events.
It is also worth noting that fibrin glue has been successfully used for pericardial hemorrhage. 20 Arai et al described a case of a nonsurgical candidate patient with right ventricle perforation requiring placement of a chest tube for pericardial drainage. In this case, the patient was found to be hemodynamically stable but had persistent hemorrhage from the perforation for several days. Fibrin glue was injected into the pericardial space, and hemostasis was achieved. Our case has demonstrated that, for a patient who is hemodynamically unstable and requires transfusion support for active bleeding, rFVIIa can be safely used with a similar outcome to Arai et al. This suggests that rVIIa may be used for life-threatening situations, and fibrin glue as an alternative option in non-life-threatening situations.
Conclusion
In conclusion, our findings suggest a beneficial effect from the local administration of low-dose rFVIIa in TAVR patients with post-procedural bleeding. The use of rFVIIa in this alternative way led to control of bleeding with no thrombotic complications, as well as limited the use of blood products. To our knowledge, this is the first reported use of this agent in this clinical setting. We suggest that use of rFVIIa in cardiac patients be decided depending on the individual merits of that particular case, and wherever feasible, low-dose local infusion be considered as an alternative option. LM
